Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.930
-0.130 (-3.20%)
At close: Dec 5, 2025, 4:00 PM EST
3.990
+0.060 (1.53%)
After-hours: Dec 5, 2025, 6:10 PM EST
Agenus Revenue
Agenus had revenue of $30.24M in the quarter ending September 30, 2025, with 20.40% growth. This brings the company's revenue in the last twelve months to $106.83M, down -33.41% year-over-year. In the year 2024, Agenus had annual revenue of $103.46M, down -33.81%.
Revenue (ttm)
$106.83M
Revenue Growth
-33.41%
P/S Ratio
0.99
Revenue / Employee
$338,066
Employees
316
Market Cap
133.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
| Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
| Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
| Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
| Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AGEN News
- 2 days ago - Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript - Seeking Alpha
- 16 days ago - Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL - Business Wire
- 18 days ago - Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC - Business Wire
- 26 days ago - Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances - Business Wire
- 4 weeks ago - Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report - Business Wire
- 7 weeks ago - Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025 - Business Wire
- 7 weeks ago - Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights - Business Wire
- 3 months ago - France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer - Business Wire